809 related articles for article (PubMed ID: 30500073)
21. Hyperfunction of CD4 CD25 regulatory T cells in de novo acute myeloid leukemia.
Wan Y; Zhang C; Xu Y; Wang M; Rao Q; Xing H; Tian Z; Tang K; Mi Y; Wang Y; Wang J
BMC Cancer; 2020 May; 20(1):472. PubMed ID: 32456622
[TBL] [Abstract][Full Text] [Related]
22. Aberrant expression of T cell activation markers and upregulation of Tregs in bone marrow and peripheral blood in acute myeloid leukemia patients.
Fang J; Zhang R; Lin X; Xu Y; Huang K; Saw PE
Hematology; 2023 Dec; 28(1):2219554. PubMed ID: 37288810
[TBL] [Abstract][Full Text] [Related]
23. Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT.
Noviello M; Manfredi F; Ruggiero E; Perini T; Oliveira G; Cortesi F; De Simone P; Toffalori C; Gambacorta V; Greco R; Peccatori J; Casucci M; Casorati G; Dellabona P; Onozawa M; Teshima T; Griffioen M; Halkes CJM; Falkenburg JHF; Stölzel F; Altmann H; Bornhäuser M; Waterhouse M; Zeiser R; Finke J; Cieri N; Bondanza A; Vago L; Ciceri F; Bonini C
Nat Commun; 2019 Mar; 10(1):1065. PubMed ID: 30911002
[TBL] [Abstract][Full Text] [Related]
24. Prospective longitudinal study of immune checkpoint molecule (ICM) expression in immune cell subsets during curative conventional therapy of head and neck squamous cell carcinoma (HNSCC).
von Witzleben A; Fehn A; Grages A; Ezić J; Jeske SS; Puntigam LK; Brunner C; Kraus JM; Kestler HA; Doescher J; Brand M; Theodoraki MN; Ottensmeier CH; Hoffmann TK; Schuler PJ; Laban S
Int J Cancer; 2021 Apr; 148(8):2023-2035. PubMed ID: 33336372
[TBL] [Abstract][Full Text] [Related]
25. Loss of CD28 expression associates with severe T-cell exhaustion in acute myeloid leukemia.
Huang Y; Zheng H; Zhu Y; Hong Y; Zha J; Lin Z; Li Z; Wang C; Fang Z; Yu X; Liu L; Xu B
Front Immunol; 2023; 14():1139517. PubMed ID: 36960073
[TBL] [Abstract][Full Text] [Related]
26. The MHC-II antigen presentation machinery and B7 checkpoint ligands display distinctive patterns correlated with acute myeloid leukaemias blast cells HLA-DR expression.
Antohe I; Tanasa MP; Dăscălescu A; Dănăilă C; Titieanu A; Zlei M; Ivanov I; Sireteanu A; Cianga P
Immunobiology; 2021 Jan; 226(1):152049. PubMed ID: 33352400
[TBL] [Abstract][Full Text] [Related]
27. Scrutinizing the Expression and Blockade of Inhibitory Molecules Expressed on T Cells from Acute Myeloid Leukemia Patients.
Abdolmaleki M; Mojtabavi N; Zavvar M; Vaezi M; Noorbakhsh F; Nicknam MH
Iran J Allergy Asthma Immunol; 2018 Jun; 17(3):265-273. PubMed ID: 29908544
[TBL] [Abstract][Full Text] [Related]
28. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies.
Graf M; Hecht K; Reif S; Pelka-Fleischer R; Pfister K; Schmetzer H
Eur J Haematol; 2004 Feb; 72(2):89-106. PubMed ID: 14962246
[TBL] [Abstract][Full Text] [Related]
29. Increased PD-1 expression of bone marrow T-cells in acute myeloid leukaemia patients after stem cell transplantation, and its association with overall survival.
You E; Park CJ; Cho YU; Jang S; Lee MY; Kim H; Koh KN; Im HJ; Choi EJ; Lee JH; Lee KH
Ann Clin Biochem; 2024 Mar; 61(2):79-89. PubMed ID: 37314798
[TBL] [Abstract][Full Text] [Related]
30. Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment.
Krönig H; Kremmler L; Haller B; Englert C; Peschel C; Andreesen R; Blank CU
Eur J Haematol; 2014 Mar; 92(3):195-203. PubMed ID: 24175978
[TBL] [Abstract][Full Text] [Related]
31. Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML.
Brück O; Blom S; Dufva O; Turkki R; Chheda H; Ribeiro A; Kovanen P; Aittokallio T; Koskenvesa P; Kallioniemi O; Porkka K; Pellinen T; Mustjoki S
Leukemia; 2018 Jul; 32(7):1643-1656. PubMed ID: 29925907
[TBL] [Abstract][Full Text] [Related]
32. Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patients.
Ngai LL; Ma CY; Maguire O; Do AD; Robert A; Logan AC; Griffiths EA; Nemeth MJ; Green C; Pourmohamad T; van Kuijk BJ; Snel AN; Kwidama ZW; Venniker-Punt B; Cooper J; Manz MG; Gjertsen BT; Smit L; Ossenkoppele GJ; Janssen JJWM; Cloos J; Sumiyoshi T
Eur J Haematol; 2021 Sep; 107(3):343-353. PubMed ID: 34053123
[TBL] [Abstract][Full Text] [Related]
33. Characteristics and clinical correlation of TIM-3 and PD-1/PD-L1 expressions in leukemic cells and tumor microenvironment in newly diagnosed acute myeloid leukemia.
Chajuwan T; Kansuwan P; Kobbuaklee S; Chanswangphuwana C
Leuk Lymphoma; 2022 Feb; 63(2):450-456. PubMed ID: 34585994
[TBL] [Abstract][Full Text] [Related]
34. A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia.
Saxena K; Herbrich SM; Pemmaraju N; Kadia TM; DiNardo CD; Borthakur G; Pierce SA; Jabbour E; Wang SA; Bueso-Ramos C; Loghavi S; Tang G; Cheung CM; Alexander L; Kornblau S; Andreeff M; Garcia-Manero G; Ravandi F; Konopleva MY; Daver N
Cancer; 2021 Oct; 127(20):3761-3771. PubMed ID: 34171128
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic criteria for hypocellular acute leukemia: a clinical entity distinct from overt acute leukemia and myelodysplastic syndrome.
Nagai K; Kohno T; Chen YX; Tsushima H; Mori H; Nakamura H; Jinnai I; Matsuo T; Kuriyama K; Tomonaga M; Bennett JM
Leuk Res; 1996 Jul; 20(7):563-74. PubMed ID: 8795690
[TBL] [Abstract][Full Text] [Related]
36. Characteristic of TIGIT and DNAM-1 Expression on Foxp3+
Jin Z; Ye W; Lan T; Zhao Y; Liu X; Chen J; Lai J; Chen S; Zhong X; Wu X
Biomed Res Int; 2020; 2020():4612952. PubMed ID: 32802845
[TBL] [Abstract][Full Text] [Related]
37. Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.
Masarova L; Kantarjian H; Garcia-Mannero G; Ravandi F; Sharma P; Daver N
Adv Exp Med Biol; 2017; 995():73-95. PubMed ID: 28321813
[TBL] [Abstract][Full Text] [Related]
38. Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy.
Knaus HA; Berglund S; Hackl H; Blackford AL; Zeidner JF; Montiel-Esparza R; Mukhopadhyay R; Vanura K; Blazar BR; Karp JE; Luznik L; Gojo I
JCI Insight; 2018 Nov; 3(21):. PubMed ID: 30385732
[TBL] [Abstract][Full Text] [Related]
39. Promoter DNA methylation and expression levels of HOXA4, HOXA5 and MEIS1 in acute myeloid leukemia.
Musialik E; Bujko M; Kober P; Grygorowicz MA; Libura M; Przestrzelska M; Juszczyński P; Borg K; Florek I; Jakóbczyk M; Siedlecki JA
Mol Med Rep; 2015 May; 11(5):3948-54. PubMed ID: 25585874
[TBL] [Abstract][Full Text] [Related]
40. Transcriptional profiling demonstrates altered characteristics of CD8
Abolhalaj M; Sincic V; Lilljebjörn H; Sandén C; Aab A; Hägerbrand K; Ellmark P; Borrebaeck CAK; Fioretos T; Lundberg K
Cancer Med; 2022 Aug; 11(15):3023-3032. PubMed ID: 35297213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
